| Literature DB >> 34354761 |
Chi-Ting Horng1,2, Jui-Wen Ma3, Po-Chuen Shieh2.
Abstract
BACKGROUND: Presbyopia is a primary cause of a decline in near vision. In this study, we developed a new mixed herbal medicine to retard presbyopic progression and increase the amplitude of accommodation (AA), which is beneficial for near vision.Entities:
Year: 2021 PMID: 34354761 PMCID: PMC8331274 DOI: 10.1155/2021/9902211
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flowchart of experiment 2.
Figure 2Flowchart of experiment 3.
Demographics of the volunteers in experiment 1.
| Age | Baseline | ||
|---|---|---|---|
| Numbers | AA | Presbyopic D | |
| 45 | 40 | 3.6 ± 0.2D | +0.7 ± 0.1D |
| 50 | 200 | 2.6 ± 0.1D | +1.2 ± 0.1D |
| 55 | 40 | 1.8 ± 0.2D | +1.6 ± 0.1D |
| 60 | 40 | 1.0 ± 0.1D | +2.0 ± 0.1D |
| 65 | 40 | 0.3 ± 0.1D | +2.4 ± 0.2D |
| 70 | 40 | 0.2 ± 0.1D | +2.3 ± 0.1D |
(1) Numbers: a total of 400 participants were gathered through an interview in our study aged between 45 and 70 years. Besides this, 240 subjects were enrolled in experiment 2 and 160 participants were separated for experiment 3 for persons with a mean age of 50 years. (2) At first, we gained the AA from subjects with different ages using the subjective push-up method. Subsequently, AA may be converted to the additional diopters of presbyopic reading glasses. (3) Near vision: test at 40 cm in front of the volunteers' eyes. (4) Age (mean age) in years. (5) AA: amplitude of accommodation. (6) D: Diopter.
The changes in AA of various ages after talking herbal drugs in experiment 2.
| Age | Times | ||||
|---|---|---|---|---|---|
| Baseline | 3rd month | 6th month | 9th month | 12th month | |
| 45 | 3.6 ± 0.2D | 3.8 ± 1.4D | 4.2 ± 1.5D | 4.0 ± 1.9D | 3.7 ± 1.5D# |
| 50 | 2.6 ± 0.1D | 2.9 ± 0.5D | 3.1 ± 0.9D | 2.9 ± 0.9D | 2.7 ± 2.0D# |
| 55 | 1.8 ± 0.2D | 2.0 ± 0.8D | 2.3 ± 1.5D | 2.3 ± 1.1D | 1.9 ± 1.2D# |
| 60 | 1.0 ± 0.1D | 1.2 ± 0.6D | 1.6 ± 0.9D | 1.3 ± 0.6D | 1.0 ± 0.6D# |
| 65 | 0.3 ± 0.1D | 0.5 ± 0.2D | 1.0 ± 0.5D | 0.9 ± 0.6D | 0.4 ± 0.2D# |
| 70 | 0.2 ± 0.1D | 0.3 ± 0.2D | 0.6 ± 0.3D | 0.5 ± 0.2D | 0.2 ± 0.2D# |
(1) All 240 participants were recruited in experiment 2, and a total of 40 volunteers with various ages took part in each group between 45 and 70 years. (2) All the volunteers took the capsules three times daily for six months and stopped treatment at the end of the sixth month. Afterward, we followed up the parameters and questions for a further six months. (3) A herbal capsule included 200 mg Cassiae Semen, 200 mg wolfberry, and 40 mg Dendrobium huoshanense (DD). (4) At first, we compared the results (at the third, sixth, ninth, and twelfth months) with the baseline. Second, we inspected the data (at the ninth and twelfth months) with the results of the sixth month. In all comparisons, the method of Scheffe's test was used for analysis. (5) When the p value was less than 0.05, it was considered as a significant difference. Hence, in the first comparison, it will be marked as , and in the second comparison, it will be marked as.
The outcomes after taking various amounts of herbal drugs in experiment 3.
| Age | Times | ||||
|---|---|---|---|---|---|
| Baseline | 3rd month | 6th month | 9th month | 12th month | |
| Placebo | 2.6 ± 0.1D | 2.6 ± 0.4D | 2.6 ± 0.5D | 2.6 ± 0.5D | 2.5 ± 0.6D |
| 1 cap/day | 2.6 ± 0.1D | 2.7 ± 0.8D | 2.8 ± 0.4D | 2.8 ± 0.9D | 2.6 ± 0.4D |
| 2 cap/day | 2.6 ± 0.1D | 2.8 ± 1.1D | 2.9 ± 0.8D | 2.9 ± 0.6D | 2.7 ± 0.8D |
| 3 cap/day | 2.6 ± 0.1D | 2.9 ± 0.9D | 3.2 ± 0.5% | 3.0 ± 0.5D | 2.7 ± 0.7D# |
(1) In experiment 3, 120 volunteers with a mean age of around 50 years were involved, and they were randomly divided into four groups. (2) Group 1 (placebo group) (n = 20): only 10 mg vitamin C daily was taken. Group 2 (n = 20): all subjects took one capsule/day. Group 3 (n = 20): all victims took two capsules daily. Group 4 (n = 20): total volunteers were fed with three capsules in each day. (3) All volunteers took the various doses of mixed herbal capsules for six months in groups 2, 3, and 4 and stopped treatment at end of the sixth month. Then, the participants received follow-up for the next six months. The associated parameters and questions were collected. (4) At first, we compared the AA of at the third, sixth, ninth, and twelfth months with the baseline using Scheffe's test. Moreover, the results at the ninth and twelfth months were recorded and compared with the outcome of the sixth month by Scheffe's test. Third, the mean AA in group 2 (1 cap/day), group 3 (2 cap/day), and group 4 (3 cap/day) was compared with the placebo group using William's test. (5) A P value less than 0.05 was considered significantly different. Hence, in the first comparison, it will be marked as, in the second comparison, it will be marked as, and in the third comparison, it will be marked as %. (6) Cap/day: capsule(s)/day.